Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coolet-D is a combination pharmaceutical product developed and marketed by Healthon Lifesciences. It contains rabeprazole sodium, a proton pump inhibitor (PPI), and domperidone, a dopamine antagonist. Rabeprazole works by inhibiting the H+/K+ ATPase enzyme system (the gastric proton pump) in the parietal cells of the stomach, thereby reducing gastric acid secretion. Domperidone acts as a peripheral dopamine D2 receptor antagonist, which increases the motility of the upper gastrointestinal tract and provides anti-emetic effects by blocking the chemoreceptor trigger zone. This combination is primarily used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, particularly when symptoms of nausea or vomiting are present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coolet-D.